

Another meaningful breakthrough for Clal Biotechnology Industries

Today, D-Pharm announced the successful results of its Phase 2b stroke* treatment drug trial.

The success with the trial has positioned D-Pharm as one of the only companies in the world to have successfully completed the development phase for a stroke treatment drug.

Avi Fischer, Chairman of the Board of Clal Biotechnology Industries, said today: “The recent developments in biotechnology companies are just a minute reflection of the great potential inherent in this industry. The results reinforce our feeling that focused management efforts alongside steadfast and patient follow-up ultimately bear fruit.”

Ruben Krupik, Chairman of D-Pharm’s Board of Directors and Chief Executive Officer of Clal Biotechnology Industries, said today: “The encouraging results in such an advanced trial are a substantial accomplishment for D-Pharm and for the industry in Israel. For us, this is further proof that the shareholders’ long-term support of the company combined with leadership, scientific innovation and a quality team, accelerates the potential for success.”

About Clal Biotechnology Industries

Clal Biotechnology Industries (CBI) was founded in 1998 and is currently among Israel’s biggest life science investors. CBI operates as an investment company with an operative foundation owned by Clal Investments and Teva. To date, the company, which is run by ARTE (headed by Ruben Krupik), has invested over 120 million dollars in 11 investments covering a wide range of life science fields. The Company is expected to finalize several additional investments during the course of 2007. Key portfolio companies: MediWound, CureTech, D-Pharm, Biokine, Polyheal, Compugen (Nasdaq: CEGN), NST, IDM (Nasdaq: IDMI).

Yours sincerely,
Ran Rahav
Spokesman for Clal Biotechnology Industries

* Strokes are the third leading cause of death in the United States, and the fifth worldwide. The cost to the health care systems in western countries is estimated at several billion dollars annually, and strokes represent a heavy burden on health systems worldwide and in the US in particular [based on US National Institutes of Health data].